Highlights
- Total Revenue (TTM)
- $31.07M
- Gross Profit (TTM)
- $30.39M
- EBITDA (TTM)
- -$95.43M
Share Price Chart
Loading graphics...
Compare stocks, funds, or ETFs
Search for stocks, ETFs, and funds for a quick comparison or use the comparison tool for more options.
Performance
Performance Chart
The chart shows the growth of an initial investment of $10,000 in CymaBay Therapeutics, Inc., comparing it to the performance of the S&P 500 index or another benchmark. All prices have been adjusted for splits and dividends.
Loading graphics...
Returns By Period
CymaBay Therapeutics, Inc.
- 1D
- —
- 1M
- —
- YTD
- —
- 6M
- —
- 1Y
- —
- 3Y*
- —
- 5Y*
- —
- 10Y*
- —
Benchmark (S&P 500 Index)
- 1D
- 2.91%
- 1M
- -5.09%
- YTD
- -4.63%
- 6M
- -2.39%
- 1Y
- 16.33%
- 3Y*
- 16.69%
- 5Y*
- 10.18%
- 10Y*
- 12.16%
Monthly Returns
| Jan | Feb | Mar | Apr | May | Jun | Jul | Aug | Sep | Oct | Nov | Dec | Total | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2024 | -0.47% | 36.92% | 0.90% | 0.00% | 37.51% | ||||||||
| 2023 | 33.81% | -4.65% | 9.00% | 23.39% | -16.54% | 21.94% | 19.18% | 5.36% | 8.44% | 9.86% | 16.79% | 23.47% | 276.71% |
| 2022 | -11.83% | 6.71% | -2.20% | -27.01% | -13.66% | 50.51% | 6.10% | 13.10% | -1.13% | -0.57% | -2.87% | 85.50% | 85.50% |
| 2021 | -6.79% | -10.28% | -5.42% | -4.63% | -2.31% | 3.07% | -9.63% | 0.51% | -7.83% | 6.85% | -15.13% | 2.11% | -41.11% |
| 2020 | -21.43% | 7.79% | -10.84% | 19.59% | 109.32% | -5.80% | 1.72% | 82.25% | 11.90% | 14.92% | -9.86% | -23.47% | 192.86% |
| 2019 | 10.55% | 35.75% | 12.45% | -3.54% | -5.70% | -40.73% | -13.69% | -4.21% | -13.51% | -12.30% | -60.80% | 11.36% | -75.10% |
Benchmark Metrics
CymaBay Therapeutics, Inc. has an annualized alpha of 51.23%, beta of 0.90, and R² of 0.03 versus S&P 500 Index. Calculated based on daily prices since February 04, 2014.
- This stock participates in less of S&P 500 Index's moves in both directions, but captures a larger share of gains (52.59%) than losses (18.66%) — typical of diversified or defensive assets.
- R² of 0.03 means this stock moves largely independently of S&P 500 Index — capture ratios reflect limited market correlation rather than active downside protection. Consider using a more representative benchmark.
- Alpha
- 51.23%
- Beta
- 0.90
- R²
- 0.03
- Upside Capture
- 52.59%
- Downside Capture
- 18.66%
Return for Risk
Return / Risk — by metrics
The table below present risk-adjusted performance metrics for CymaBay Therapeutics, Inc. (CBAY) and compare them to a chosen benchmark (S&P 500 Index).
Risk / return metrics aren't available yet — we need at least 12 months of trading data to calculate them.
Dividends
Dividend History
Drawdowns
Drawdowns Chart
The Drawdowns chart displays portfolio losses from any high point along the way. Drawdowns are calculated considering price movements and all distributions paid, if any.
Loading graphics...
Worst Drawdowns
The table below displays the maximum drawdowns of the CymaBay Therapeutics, Inc.. A maximum drawdown is a measure of risk, indicating the largest reduction in portfolio value due to a series of losing trades.
The maximum drawdown for the CymaBay Therapeutics, Inc. was 92.85%, occurring on Feb 11, 2016. Recovery took 505 trading sessions.
Depth | Start | To Bottom | Bottom | To Recover | End | Total |
|---|---|---|---|---|---|---|
| -92.85% | Feb 19, 2015 | 248 | Feb 11, 2016 | 505 | Feb 13, 2018 | 753 |
| -91.75% | Mar 5, 2018 | 514 | Mar 18, 2020 | 875 | Sep 8, 2023 | 1389 |
| -44.44% | Mar 5, 2014 | 119 | Aug 21, 2014 | 85 | Dec 22, 2014 | 204 |
| -28.32% | Sep 13, 2023 | 22 | Oct 12, 2023 | 24 | Nov 15, 2023 | 46 |
| -10.19% | Jan 9, 2015 | 9 | Jan 22, 2015 | 7 | Feb 2, 2015 | 16 |
Volatility
Volatility Chart
The chart below shows the rolling one-month volatility.
Loading graphics...
Financials
Financial Performance
The chart below illustrates the trends in the financial health of CymaBay Therapeutics, Inc. over time, highlighting three key metrics: Total Revenue, Earnings Before Interest and Taxes (EBIT), and Net Income.
Valuation
The Valuation section provides an overview of how CymaBay Therapeutics, Inc. is priced in the market compared to other companies in the Biotechnology industry. It includes key financial ratios that help investors assess whether the stock is undervalued or overvalued.
Income Statement
| TTM | |
|---|---|
Revenue | — |
Total Revenue | — |
Cost Of Revenue | — |
Gross Profit | — |
Operating Expenses | — |
Selling, General & Admin Expenses | — |
R&D Expenses | — |
Depreciation And Amortization | — |
Total Operating Expenses | — |
Income | — |
Income Before Tax | — |
Operating Income | — |
EBITDA | — |
EBIT | — |
Earnings From Continuing Operations | — |
Net Income | — |
Income Tax Expense | — |
Other Non-Operating Income (Expenses) | — |
Extraordinary Items | — |
Discontinued Operations | — |
Effect Of Accounting Charges | — |
Non Recurring | — |
Minority Interest | — |
Other Items | — |
Interest Income | — |
Interest Expense | — |
Net Interest Income | — |